SCHEMBL5430140

SCHEMBL5430140

Cc1n[nH]c2ccc(-c3cc(-c4ccccc4)[nH]c(=O)c3)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.50
JAK2 O60674 3/20 0.47
TNKS2 Q9H2K2 1/20 0.45
HSD17B10 Q99714 3/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 2/20 0.43
TP53 P04637 2/20 0.43
HPGD P15428 2/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
BRD4 O60885 1/20 0.43
PIK3C3 Q8NEB9 3/20 0.43
CYP1A2 P05177 1/20 0.42
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
AXL P30530 1/20 0.41
ALDH1A1 P00352 2/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27968550 0.82 MKNK1 (0.71) MKNK1JAK2KDM4EHPGDCYP1A2
SCHEMBL5427424 0.80 CDC7 (0.61) MKNK1HSD17B10KDM4EHPGDGSK3A
SCHEMBL3341445 0.78 GCGR (0.43) MKNK1TNKS2PIK3C3GSK3B
SCHEMBL8799713 0.74 HPGD (0.51) TNKS2HSD17B10LMNASMN1; SMN2KDM4E
SCHEMBL8987066 0.74 HPGD (0.51) TNKS2HSD17B10LMNASMN1; SMN2KDM4E
SCHEMBL5432014 0.74 CDC7 (0.67) GSK3AGSK3B
SCHEMBL6756097 0.73 TAS2R38 (0.60) TNKS2HSD17B10LMNASMN1; SMN2KDM4E
SCHEMBL8987272 0.73 NOTUM (0.50) TNKS2HSD17B10LMNASMN1; SMN2KDM4E
SCHEMBL5426265 0.72 MKNK1 (0.54) MKNK1JAK2TNKS2KDM4ETP53
SCHEMBL21509969 0.72 MAP2K4 (0.60) MKNK1JAK2LMNAGSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-12-20 US disclosed
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-12-20 US disclosed
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-12-20 US disclosed
WO-2007124288-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS AG (CH) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 CDC7, CDC37, CDC73 MKNK1 1096/4885JAK2 4697/4885TNKS2 1626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.